Ambrosini Valentina, Rubello Domenico, Castellucci Paolo, Nanni Cristina, Farsad Mohsen, Zinzani Pierluigi, Alavi Abass, Tehranipour Neda, Al-Nahhas Adil, Fanti Stefano
Department of Nuclear Medicine - PET Unit, Policlinico S. Orsola-Malpighi Hospital, Bologna, Italy.
Nucl Med Rev Cent East Eur. 2006;9(1):37-40.
The aim of the study was to evaluate the usefulness of 18F-FDG-PET in patients with gastric lymphoma, in particular those affected by mucosa-associated lymphoid tissue (MALT) type and aggressive gastric non-Hodgkin's lymphoma (NHL).
The study group consists of 15 patients with a previous diagnosis of gastric NHL referred to our PET centres in Bologna Hospital and Rovigo Hospital, Italy, in the period 2003-2004. In 9/15 patients the subsequent histological evaluation was consistent with a gastric MALT lymphoma, while aggressive gastric NHL was diagnosed in the other 6/15. PET scan was carried out in patients with known active disease in order to stage or re-stage disease prior to treatment or in patients in complete clinical remission to monitor disease during follow up. Patients were considered in complete clinical remission if free from disease for at least 8 months after chemotherapy or surgery.18F-FDG PET was performed following standard procedures.
Overall 18F-FDG-PET was true positive in all cases of gastric MALT and non-MALT aggressive NHL with known active disease, while no pathological 18F-FDG uptake was evident in the subjects who were in complete clinical remission. The degree of 18F-FDG uptake (mean SUVmax values) in MALT lymphoma was much less intense in comparison to aggressive gastric NHL, suggesting a prognostic role of SUV calculation in gastric lymphomas.
Our data demonstrate the significant accuracy of 18F-FDG-PET in detecting active disease in gastric lymphoma of both MALT and non-MALT NHL type. A higher SUV value appears to be related to a more aggressive disease.
本研究的目的是评估18F-FDG-PET在胃淋巴瘤患者中的应用价值，尤其是在黏膜相关淋巴组织（MALT）型和侵袭性胃非霍奇金淋巴瘤（NHL）患者中的应用价值。
研究组由2003年至2004年期间转诊至意大利博洛尼亚医院和罗维戈医院PET中心的15例先前诊断为胃NHL的患者组成。15例患者中，9例随后的组织学评估与胃MALT淋巴瘤一致，另外6例诊断为侵袭性胃NHL。对已知患有活动性疾病的患者进行PET扫描，以便在治疗前对疾病进行分期或重新分期，或对处于临床完全缓解期的患者进行随访以监测疾病。如果患者在化疗或手术后至少8个月无疾病，则认为其处于临床完全缓解期。18F-FDG PET按照标准程序进行。
总体而言，18F-FDG-PET在所有已知患有活动性疾病的胃MALT和非MALT侵袭性NHL病例中均为真阳性，而在临床完全缓解的患者中未发现病理性18F-FDG摄取。与侵袭性胃NHL相比，MALT淋巴瘤中18F-FDG摄取程度（平均SUVmax值）要低得多，这表明SUV计算在胃淋巴瘤中具有预后作用。
我们的数据表明，18F-FDG-PET在检测MALT和非MALT NHL型胃淋巴瘤的活动性疾病方面具有显著的准确性。较高的SUV值似乎与更具侵袭性的疾病有关。
